CAM
RPRX icon

Cresset Asset Management’s Royalty Pharma RPRX Stock Holding History

Cresset Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,385
Closed -$775K – 2132
2024
Q3 		$775K Buy
27,385
+3,270
+14% +$90.6K ﹤0.01% 1295
2024
Q2 		$636K Sell
24,115
-3,022
-11% -$83.8K ﹤0.01% 1329
2024
Q1 		$824K Buy
27,137
+6,344
+31% +$187K ﹤0.01% 1078
2023
Q4 		$584K Buy
20,793
+13,054
+169% +$359K ﹤0.01% 1148
2023
Q3 		$210K Buy
+7,739
New +$230K ﹤0.01% 1600

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cresset Asset Management's RPRX Position: Q4 2024 in Review

Cresset Asset Management sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 27,385 shares — an estimated $775K sold.

Cresset Asset Management first reported a position in RPRX in Q3 2023 and held it in 5 quarters. The position peaked at $824K in Q1 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Cresset Asset Management reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 27,385 Royalty Pharma shares in Q4 2024, an estimated $775K.
  • Cresset Asset Management first reported a position in Royalty Pharma in Q3 2023 and held it in 5 quarters.
  • Cresset Asset Management's Royalty Pharma position peaked at $824K in Q1 2024.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.